



2015093590-14

UCC FINANCING STATEMENT

FOLLOW INSTRUCTIONS

A. NAME & PHONE OF CONTACT AT FILER (optional) Michell Do / (949) 721-5265
B. E-MAIL CONTACT AT FILER (optional) Michell.Do@Knobbe.com
C. SEND ACKNOWLEDGMENT TO: (Name and Address) Knobbe, Martens, Olson & Bear, LLP Attn: Michell Do 2040 Main St., 14th Floor Irvine, CA 92614

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

1. DEBTOR'S NAME: Provide only one Debtor name (1a or 1b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor's name); if any part of the Individual Debtor's name will not fit in line 1b, leave all of item 1 blank, check here and provide the Individual Debtor information in item 10 of the Financing Statement Addendum (Form UCC1Ad)

1a. ORGANIZATION'S NAME TRIEPE AB					
OR	1b. INDIVIDUAL'S SURNAME		FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX
1c. MAILING ADDRESS HALSOVAGEN 7			CITY HUDDINGE	STATE	POSTAL CODE SE-141 57
				COUNTRY SE	

2. DEBTOR'S NAME: Provide only one Debtor name (2a or 2b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor's name); if any part of the Individual Debtor's name will not fit in line 2b, leave all of item 2 blank, check here and provide the Individual Debtor information in item 10 of the Financing Statement Addendum (Form UCC1Ad)

2a. ORGANIZATION'S NAME					
OR	2b. INDIVIDUAL'S SURNAME		FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX
2c. MAILING ADDRESS			CITY	STATE	POSTAL CODE
				COUNTRY	

3. SECURED PARTY'S NAME (or NAME of ASSIGNEE or ASSIGNOR SECURED PARTY). Provide only one Secured Party name (3a or 3b)

3a. ORGANIZATION'S NAME KNOBBE, MARTENS, OLSON & BEAR, LLP					
OR	3b. INDIVIDUAL'S SURNAME		FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX
3c. MAILING ADDRESS 2040 MAIN ST., 14TH FLOOR			CITY IRVINE	STATE CA	POSTAL CODE 92614
				COUNTRY USA	

4. COLLATERAL: This financing statement covers the following collateral:

SEE ATTACHMENT.

5. Check only if applicable and check only one box: Collateral is held in a Trust (see UCC1Ad, item 17 and Instructions) being administered by a Decedent's Personal Representative

6a. Check only if applicable and check only one box:
 Public-Finance Transaction Manufactured-Home Transaction A Debtor is a Transmitting Utility

6b. Check only if applicable and check only one box:
 Agricultural Lien Non-UCC Filing

7. ALTERNATIVE DESIGNATION (if applicable): Lessor/Lessee Consignor/Consignee Seller/Buyer Bailor/Bailee Licensee/Licensee

8. OPTIONAL FILER REFERENCE DATA:
TRIEPE - UCCI

Handwritten initials

Handwritten initials

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Title of Invention
6933366			8/23/2005	SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO BACTERIAL ADHESION RECEPTORS
6245895			6/12/2001	ANTIGEN/ANTIBODY SPECIFICITY EXCHANGER
7019111			3/28/2006	GLYCOSYLATED LIGAND/RECEPTOR SPECIFICITY EXCHANGERS SPECIFIC FOR BACTERIAL ADHESION RECEPTORS
6960569			11/1/2005	HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE
7439347			10/21/2008	HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE
7226912			6/5/2007	HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Title of Invention
13/514269	6/6/2012	7968697	6/28/2011	A HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE
				CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAAG)
		8071561	12/6/2011	IMMUNOGEN PLATFORM
		8883169	11/11/2014	IMMUNOGEN PLATFORM
14/527669	10/29/2014	8258275	9/4/2012	IMMUNOGEN PLATFORM
13/511353	8/27/2012			T CELL RECEPTORS SPECIFIC FOR IMMUNODOMINANT CTL
14/692667	4/21/2015	8445663	5/21/2013	COMPOSITIONS AND METHODS THAT ENHANCE AN IMMUNE RESPONSE

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Title of Invention
7022830			4/4/2006	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
7307066			12/11/2007	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
7318926			1/15/2008	GLYCOSYLATED SPECIFICITY EXCHANGERS
7332166			2/19/2008	GLYCOSYLATED SPECIFICITY EXCHANGERS
8303956			11/6/2012	GLYCOSYLATED SPECIFICITY EXCHANGERS
7335359			2/26/2008	GLYCOSYLATED SPECIFICITY EXCHANGERS
7534435			5/19/2009	GLYCOSYLATED SPECIFICITY EXCHANGERS
8658179			2/25/2014	GLYCOSYLATED SPECIFICITY EXCHANGERS
9079962			7/14/2015	GLYCOSYLATED SPECIFICITY EXCHANGERS
7566812			7/28/2009	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HCV) AND IDENTIFICATION OF HCV THERAPEUTICS

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Title of Invention
14/221662	3/21/2014			SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES
14/125905	12/12/2013			INJECTION NEEDLE AND DEVICE
		6858590	2/22/2005	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		7241440	7/10/2007	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		7244715	7/17/2007	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		6680059	1/20/2004	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		7261883	8/28/2007	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		7244422	7/17/2007	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		7223743	5/29/2007	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Title of Invention
		7638499	12/29/2009	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
		7943149	5/17/2011	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
		8163547	4/24/2012	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
		8163712	4/24/2012	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
		8158602	4/17/2012	HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE
13/441305	4/6/2012			HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE

All of dector's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
2421877	9/19/2001			CA	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
		2002223973	7/19/2007	AU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
		ZL01816780.2	2/27/2008	CN	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
		2007203138	9/8/2011	AU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
		2300391	6/10/2007	RU	LIGAND/RECEPTOR SPECIFICITY EXCHANGERS THAT REDIRECT ANTIBODIES TO RECEPTORS ON A PATHOGEN
		1311289	10/17/2007	AT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		2001292151	9/14/2006	AU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
		1311289	10/17/2007	BE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1311289	10/17/2007	CH	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		ZL01815071.3	7/9/2008	CN	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		60130998.7	10/17/2007	DE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1311289	10/17/2007	EP	VACCINES CONTAINING RIBAVIRIN
		1311289	10/17/2007	ES	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1311289	10/17/2007	FR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1311289	10/17/2007	GB	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1311289	10/17/2007	IE	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
		1311289	10/17/2007	IT	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		5175417	1/11/2013	JP	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		10-0801123	1/29/2008	KR	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		2006203358	10/30/2008	AU	VACCINES CONTAINING RIBAVIRIN AND METHODS OF USE THEREOF
		1947185	7/20/2011	EP	HCVNS3/4 ENCODING NUCLEIC ACID
		2003290385	3/4/2010	AU	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE
		ZL2003801092087	12/9/2009	CN	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE
		1567190	4/10/2013	EP	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE
		1081973	1/30/2014	HK	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
2012200059	2/5/2004			AU	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE
200480003737.3	2/5/2004			CN	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS
10164941.6	2/5/2004	10-1144642	5/3/2012	KR	A HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4 FUSION GENE
2006-502508	2/5/2004			JP	ANTIGEN/ANTIBODY OR LIGAND/RECEPTOR GLYCOSYLATED SPECIFICITY EXCHANGERS
		541883	4/9/2009	NZ	GLYCINAMIDE DERIVATIVE FOR INHIBITING REPLICATION
		1781690	6/29/2011	EP	TRANSGENIC MOUSE MODELS OF HEPATITIS C VIRUS (HVC) AND IDENTIFICATION OF HCV THERAPEUTICS

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
6795529.4	5/24/2006			EP	HEPATITIS C VIRUS NON-STRUCTURAL NS3/4A FUSION GENE
2010332400	6/26/2012			AU	
2784488	6/14/2012			CA	
201080062289.X	7/24/2012			CN	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)
10816307.2	7/13/2012			EP	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)
1451/MUMNP/2012	6/11/2012			IN	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)
		5785559	7/31/2015	JP	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)
10-2012-7018532	7/16/2012			KR	
		2539991	12/11/2014	RU	CODON-OPTIMIZED HEPATITIS B VIRUS CORE ANTIGEN (HBCAG)
10796478.5	11/23/2010			EP	T CELL RECEPTORS SPECIFIC FOR IMMUNO-DOMINANT CTL EPITOPES OF HCV

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
10710625.4	1/29/2010			EP	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN
12105381.2	6/1/2012			HK	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN
6734/DELNP/2011	1/29/2010			IN	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN
PCT/IB2010/000324	1/29/2010			WO	CODON-OPTIMISED HEPATITIS B VIRUS CORE ANTIGEN
2012270015	12/17/2013			AU	
2839196	12/12/2013			CA	
201280039644.0	2/13/2014			CN	INJECTION NEEDLE AND DEVICE
12737344.7	1/13/2014			EP	INJECTION NEEDLE AND DEVICE
14110613	10/23/2014			HK	INJECTION NEEDLE AND DEVICE
10993/DELNP/2013	12/20/2013			IN	
10-2014-7000981	1/14/2014			KR	

All of debtor's intellectual property that is or has ever been the subject of secured party's representation and all files and records relating thereto, any recoveries from litigation involving such intellectual property, including, without limitation, any judgments, amounts paid in settlement, insurance proceeds and any awards of attorneys' fees and costs, and any other proceeds of such intellectual property, including, but not limited to, the property described below.

Non U.S. Patent & Patent Applications

Application No.	App. Filing Date	Patent No.	Issued Date	Country	Title of Invention
PCT/IB2012/001321	6/13/2012			WO	INJECTION NEEDLE, DEVICE, IMMUNOGENIC COMPOSITIONS AND METHOD OF USE
PCT/IB2013/003034	10/4/2013			WO	IMMUNOGENIC COMPOSITIONS FOR INHIBITING HEPATITIS D VIRUS
PCT/US2014/037918	5/13/2014			WO	TREATMENT OF HEPATITIS D VIRUS INFECTIONS BY REDIRECTION OF T CELLS
PCT/US2014/056158	9/17/2014			WO	